| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
AC Immune SA$2.45
+0.06 (+2.51%)
D 36Pipeline Score Overvalued Pharma · Clinical
Market Cap
246.29 M
EPS
-0.82
P/E Ratio
-2.95 $
Value Trade
601.48 K
-0.35 %
Week
-5.03 %
1 Month
11.86 %
3 Month
-3.41 %
6 Month
-55.99 %
5 Year
-79.94 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
250.03 K
52 Week Range
1.63 - 4
% held by Insiders
38.52 %
% held by Institutions
24.77 %
Enterprise Value
158.57 M
Total Shares
101.73 M
Short %
5.4 %
Float Shares
74.67 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AC Immune SA
478Total events
13Upcoming
132Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
◆Poster PresentationPresentation
Subscribe to view catalyst details
TBD
◆Poster PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-12 | ACI-19764 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-07-12 | ACI-19764 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-07-12 | ACI-19764 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D36
Pipeline Score $49M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 50%
Micro Cap (rank 457 of 912)
Percentile RankAC Immune SA faces pipeline headwinds (36/100), with $432M risk-adjusted pipeline value, led by ACI-7104.056 at Dose A in Parkinson Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACI-7104.056 at Dose A Monoclonal antibody | Parkinson Disease | Phase 2 | NCT06015841 | 16% | $135M | ACTIVE NOT_RECRUITING | 150 | AVERAGE | B (69) | Jan 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ACI-24 Fast Track | prodromal Alzheimer's disease | Phase 1b/2 | 2026-06-30 | 74 patients; no evidence of amyloid-related imaging abnormalities-edema (ARIA-E); Anti-Abeta antibody responses were detected at every dose level with a dose response Read More | AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease Read More | |
ACI-24 Fast Track | prodromal Alzheimer's disease | Phase 1b/2 | 2026-06-30 | 74 patients; no evidence of amyloid-related imaging abnormalities-edema (ARIA-E); Anti-Abeta antibody responses were detected at every dose level with a dose response Read More | AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease Read More | |
ACI-24 Fast Track | prodromal Alzheimer's disease | Phase 1b/2 | 2026-06-30 | 74 patients; no evidence of amyloid-related imaging abnormalities-edema (ARIA-E); Anti-Abeta antibody responses were detected at every dose level with a dose response Read More | AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACIU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACIU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACIUAC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune SA will present three key studies at the Alzheimer's Association International Conference 2026, highlighting advancements in neurodegenerative disease therapies. The presentations will showcase a TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor in Phase 1, and an aggregation inhibitor targeting alpha-synuclein pathology. These developments underscore the company's commitment to innovative treatments for conditions like Alzheimer's and Parkinson's diseases.
Read more →ACIU▼ -10.5%on this news
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
AC Immune announced interim results from the Phase 1b/2 ABATE trial of ACI-24 in patients with prodromal Alzheimer's disease. The treatment was found to be generally safe, with no evidence of amyloid-related imaging abnormalities. A dose-response relationship for anti-Abeta antibodies was observed, and a new cohort is being tested with an additional adjuvant to enhance immunogenicity.
Read more →ACIU▲ +6.6%on this news
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune has secured a $4 million research grant from the Goradia Family to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104, targeting early Parkinson's disease. This funding will allow for an additional two years of study to assess long-term safety and efficacy. Interim results have shown promise, indicating potential disease-modifying effects.
Read more →ACIU▲ +6.6%on this newsshared move
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1
AC Immune SA has received a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to support the continued development of ACI-7104 in early Parkinson's disease. This funding will facilitate the extension of Part 1 of the Phase 2 VacSYn trial, following positive interim results that indicated the compound could have a disease-modifying effect. The grant aims to generate crucial data to aid the treatment of patients at the early stages of this neurodegenerative condition. AC Immune's CEO expressed gratitude for the grant, highlighting the company's commitment to precision prevention in neurodegenerative diseases.
Read more →ACIU▲ +6.6%on this newsshared move
NASDAQ: ACIU | AGM Presentation
AC Immune presented updates at its Annual General Meeting on June 11, 2026, highlighting its innovative approaches to neurodegenerative diseases through active immunotherapy. The company reported a robust cash reserve that provides financial stability until Q4 2027 and shared positive results from ongoing clinical trials. However, it also cautioned about inherent risks and uncertainties tied to its forward-looking statements and operations affected by COVID-19. AC Immune aims to lead in precision prevention and treatment in the neurodegenerative space with its promising pipeline.
Read more →ACIUAC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune presented new Phase 1 data at the 2026 TDP43 Summit, showing that its PET tracer ACI-19626 has significantly higher uptake in ALS patients compared to healthy controls. The findings suggest the tracer's potential for early diagnosis and intervention in neurodegenerative diseases. The ongoing trial continues to demonstrate a favorable safety profile.
Read more →ACIUto the Company's Form 6 - K on 13 March 2026 can be downloaded from the Company's website at ir.acimmune.com/events/agm . It explains the governance framework and the principles underlying the compensation structure at A
AC Immune has made notable advancements in its clinical pipeline, especially with ACI-7104 showing promise in treating Parkinson's disease. The company has reported good safety data and positive immunogenicity in key trials, affirming their strategy for precision prevention of neurodegenerative diseases. While they face challenges, including a paused recruitment for one trial and workforce reductions, their ongoing investment in research and collaborations indicates strong potential for future success. AC Immune will be focusing on class-leading products to treat and prevent neurodegenerative diseases moving forward.
Read more →ACIUAC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune's CEO, Dr. Andrea Pfeifer, will retire at the upcoming AGM after 23 years. Martin Zügel, the Board Chair, will take over as interim CEO while a search for a permanent successor is conducted. Dr. Pfeifer will continue to support the company as an Advisor and Honorary Chair. The company remains strong with a promising pipeline and strategic partnerships.
Read more →ACIUAC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune reported financial and corporate updates for Q1 2026, highlighting the initiation of a Phase 1 trial for ACI-19764 and the final cohort in the ABATE trial for ACI-24. The company amended its collaboration with Eli Lilly, reflecting progress in targeting Tau proteins. Despite a net loss of CHF 14.8 million, AC Immune's cash resources are projected to sustain operations through Q4 2027.
Read more →ACIUAC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune has initiated the final cohort in its Phase 1b/2 ABATE trial for ACI-24, an anti-Abeta immunotherapy for Alzheimer's disease. The first patient in Cohort AD4 has been treated, triggering a $12 million milestone payment from Takeda. Results from earlier cohorts are expected in Q2 2026, with promising early data on safety and immunogenicity.
Read more →ACIUAC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 millio
AC Immune SA has announced the initiation of the final cohort, AD4, in its ongoing Phase 1b/2 ABATE trial of the anti-Abeta immunotherapy ACI-24 for Alzheimer's disease. The dosing of the first patients in this cohort triggers a $12 million milestone payment from Takeda, which is collaborating on this project. Preliminary data indicates that ACI-24 is generally safe and has induced positive antibody responses against amyloid beta, a key factor in Alzheimer's pathology. The trial aims to expand on these findings with a total of 36 subjects treated for 12 months, followed by a potential cohort expansion to 112 participants.
Read more →ACIUAC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expe
AC Immune SA (NASDAQ: ACIU) provided its financial and corporate updates for Q1 2026, announcing the initiation of a Phase 1 trial for their NLRP3 inhibitor ACI-19764. The company reported a cash position expected to sustain operations through Q4 2027, alongside promising partnerships with Takeda and Eli Lilly. Despite a net operating loss of CHF 14.8 million, AC Immune is optimistic about multiple upcoming milestones in 2026, including Phase 2 data readouts and the potential to modify disease pathology for neurodegenerative diseases.
Read more →ACIU▲ +15.2%on this news
AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progr
AC Immune SA has amended its 2018 collaboration agreement with Eli Lilly to enhance research on Tau aggregation inhibitors for Alzheimer's and other neurodegenerative diseases. The agreement includes a CHF10 million upfront payment and eligibility for over CHF1.7 billion in milestone payments. AC Immune's CEO highlighted the potential of their Morphomer small molecules to target intracellular Tau. Furthermore, promising preclinical data supports the clinical relevance of these candidates in inhibiting Tau aggregation.
Read more →ACIU▲ +15.2%on this news
AC Immune Announces Amendment to Morphomer Tau License And Collaboration Agreement With Lilly
AC Immune Announces Amendment to Morphomer Tau License And Collaboration Agreement With Lilly
Read more →ACIUAC Immune Presents First in Vivo Images of Brain TDP 43 Pathology From Phase 1 Trial of PET Tracer ACI 19626 at AD Pdtm 2026
AC Immune Presents First in Vivo Images of Brain TDP 43 Pathology From Phase 1 Trial of PET Tracer ACI 19626 at AD Pdtm 2026
Read more →ACIUAC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune SA reported its financial results for 2025, highlighting promising Phase 2 interim results for ACI-7104, which may slow Parkinson's disease progression. The company initiated a Phase 1 trial for ACI-19764, a NLRP3 inhibitor. Despite a cash position of CHF 91.4 million, the company reported a net loss of CHF 70.5 million and a significant drop in contract revenues compared to the previous year.
Read more →ACIUAC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune announced it will host a symposium on precision prevention for Parkinson's disease and present its TDP-43 PET-tracer ACI-19626 at the AD/PD™ 2026 conference in Copenhagen. The symposium will feature discussions on shifting treatment approaches and interim results from ongoing trials. The event aims to showcase advancements in neurodegenerative disease research.
Read more →ACIU▲ +7.5%on this news
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
AC Immune has initiated a Phase 1 clinical trial for ACI-19764, an oral NLRP3 inhibitor. The trial aims to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers. Initial data is expected in late 2026, with preclinical studies indicating strong potential for treating neurodegenerative diseases. The trial is being conducted in Europe.
Read more →ACIU▲ +7.5%on this newsshared move
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor NLRP3 inhibitors are a major new class of compounds linke
AC Immune SA has initiated a Phase 1 clinical trial for ACI-19764, a small molecule NLRP3 inhibitor, with the first participant successfully dosed. This trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers. The drug shows promise based on preclinical data, indicating it may significantly reduce neuroinflammation associated with several neurodegenerative diseases. Initial results from the trial are expected in the latter half of 2026.
Read more →ACIU▲ +15.4%on this news
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune announced positive interim results from its Phase 2 VacSYn trial for ACI-7104.056, an immunotherapy for early Parkinson's disease. The data indicates potential slowing of disease progression and stabilization of biomarkers. The company plans to seek regulatory feedback to accelerate development towards registration.
Read more →ACIU▲ +15.4%on this newsshared move
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease Results show, for the first time, that targeting underlying a-syn pathology with an ac
AC Immune has announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy targeting alpha-synuclein in early Parkinson's disease. The trial indicates a potential slowing of disease progression, with consistent results across multiple biomarkers suggesting stabilization. The data shows promise for further development and regulatory discussions, as AC Immune aims for accelerated clinical development. Final data from the study is anticipated in mid-2026.
Read more →ACIUAC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune SA will present at the Jefferies 2025 London Healthcare Conference from November 17-20, 2025. The company management will engage in a fireside chat on November 18, 2025, and hold one-on-one investor meetings. AC Immune is recognized for its innovative approaches to neurodegenerative diseases.
Read more →ACIUAC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune SA reported its Q3 2025 financial results and highlighted advancements in its pipeline for neurodegenerative diseases. The company is focusing on its most valuable assets and has extended its cash runway to Q3 2027. Key developments include ongoing Phase 2 trials for Alzheimer's and Parkinson's diseases, with interim results expected soon. The company also published promising data on its immunotherapy platforms.
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,208 2,651 Right-of-use assets 6 4,653 5,437
AC Immune SA's latest financial report for the period ending September 30, 2025, indicates a significant downturn compared to the previous year. The company reported a loss of 15,858 CHF for the three months, a stark contrast to the profit of 5,503 CHF during the same period in 2024. Accumulated losses rose notably, compounded by a substantial decrease in total assets and current liabilities. Overall, these results highlight ongoing financial struggles for the clinical-stage biopharmaceutical firm.
Read more →ACIUAC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
AC Immune has appointed Prof. Catherine Mummery as the Chair of its Clinical Advisory Board. Prof. Mummery brings extensive experience in dementia clinical trials and will guide the company's clinical development strategy. Her involvement is expected to enhance AC Immune's pipeline, which includes several active immunotherapies in various stages of development. The CAB will provide critical insights into AC Immune's precision prevention approaches for neurodegenerative diseases.
Read more →ACIU▲ +15.7%on this news· ran to +37% by day 3shared move
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
AC Immune SA announced the publication of preclinical data on ACI-19626, a TDP-43 PET tracer, in Nature Communications. This first-in-class imaging tool could enhance the diagnosis of neurodegenerative diseases like ALS and Alzheimer's. ACI-19626 demonstrates promising characteristics for detecting TDP-43 pathology and is advancing into Phase 1 clinical trials.
Read more →ACIU▲ +6.6%on this news
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
AC Immune SA announced the peer-reviewed publication of results from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's disease. The study demonstrated a robust immune response with no safety concerns. ACI-35.030 is now advancing to the Phase 2b ReTain trial, aiming to assess its potential to modify disease progression.
Read more →ACIUAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune SA is refining its focus on key assets in neurodegenerative disease therapies, including immunotherapy programs and small molecule targets. The company plans to reduce its workforce by 30% while extending its cash runway to Q3 2027. CEO Dr. Andrea Pfeifer emphasized the progress made with product candidates and ongoing collaborations with major pharmaceutical partners.
Read more →ACIUAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce r
AC Immune SA has announced a strategic review aimed at focusing its investments on key assets, particularly in its clinical-stage immunotherapy programs. The company plans to reduce its workforce by approximately 30%, a move that it states is necessary for extending its operational cash runway until the end of Q3 2027. CEO Dr. Andrea Pfeifer noted that the changes are expected to bolster progress towards significant milestones within the next two years. The company maintains its timelines for interim clinical data from various programs, indicating ongoing commitment despite reductions in resources.
Read more →ACIU▲ +11.6%on this news
Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,490 2,651 Right-of-use assets 6 4,926 5,437 Inta
AC Immune SA has released its unaudited condensed consolidated balance sheets as of June 30 and December 31, comparing assets from 2024 and 2025. The company reported non-current assets including property, plant and equipment, right-of-use assets, and intangible assets. Long-term financial assets also showed a slight increase. Overall, the financial status indicates stability, but no significant changes or developments are highlighted.
Read more →ACIU▲ +11.6%on this news
AC Immune Reports Second Quarter 2025 Financial Results And Provides a Corporate Update
AC Immune Reports Second Quarter 2025 Financial Results And Provides a Corporate Update
Read more →ACIU▼ -5.1%on this news
NASDAQ: ACIU | AGM Presentation, June 2025 2025 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting
AC Immune's June 2025 AGM presentation highlighted the company's advancements in targeting neurodegenerative diseases through precision medicine and active immunotherapy. The firm reported a strong cash position with reserves expected to last through Q1 2027 and outlined key achievements from 2024, including collaborations with Takeda and Janssen. Their diverse pipeline includes therapies focused on Alzheimer's disease and related disorders. However, the company also acknowledges significant risks associated with its forward-looking statements and external partnerships.
Read more →ACIUto the Company's Form 6 - K on
AC Immune SA invites shareholders to its 2025 Annual General Meeting where it will discuss significant advancements in its neurodegenerative disease therapies. The company focuses on Alzheimer's and Parkinson's diseases and highlights notable achievements in active immunotherapies, including successful Phase 2b trials with partners like Janssen Pharmaceuticals. Financially, AC Immune has strengthened its resources to support continued development, ending 2024 with CHF 165.5 million in cash. The leadership team has also been bolstered to achieve its goals in precision medicine.
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,761 2,651 Right-of-use assets 6 5,186 5,437 Int
AC Immune SA has released its interim consolidated financial statements for the first quarter of 2025, reporting an operating loss of CHF 19,370,000. This represents an increase in loss compared to the previous year's loss of CHF 20,068,000. The total shareholders' equity has declined to CHF 94,798,000, down from CHF 112,270,000 at the end of 2024. Additionally, the company's cash and cash equivalents have experienced a significant decrease, indicating potential liquidity challenges.
Read more →ACIUAC Immune Reports First Quarter 2025 Financial Results And Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results And Provides a Corporate Update
Read more →ACIUAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune announced positive interim results from the Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The trial showed a strong safety profile and significant immunogenicity, with antibody responses increasing over time. The company plans to report further data in 2025 and may expand the trial to include more patients.
Read more →ACIU▼ -6.6%on this news
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune SA announced its participation in the AD/PD™ 2025 conference in Vienna, where it will present its precision medicine pipeline. The company will host an industry symposium focusing on active immunotherapies for neurodegenerative diseases. Key presentations will include discussions on targeting alpha-synuclein and the development of new therapeutic agents.
Read more →ACIUAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential mi
AC Immune SA reported its financial results for the full year 2024, highlighting a significant partnership with Takeda for ACI-24.060. The deal includes an upfront payment of $100 million and potential milestone payments totaling up to $2.1 billion. The company remains focused on advancing its pipeline of therapies for neurodegenerative diseases. However, AC Immune also reported a net loss of CHF 50.916 million, indicating continued financial challenges amidst their progress.
Read more →ACIUAC Immune Reports Full Year 2024 Financial Results And Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results And Provides a Corporate Update
Read more →ACIUAC Immune to Participate in Upcoming Investor Conferences
AC Immune to Participate in Upcoming Investor Conferences
Read more →ACIUAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse ev
AC Immune has released interim safety data from its Phase 1b/2 ABATE trial evaluating ACI-24.060 for individuals with Down syndrome. The data revealed that the investigational immunotherapy was generally safe with no serious adverse events or significant side effects reported in the initial cohorts. The trial aims to establish ACI-24.060 as a potential treatment for Alzheimer's disease in a vulnerable population. The next phase will involve assessing higher doses of the drug to further explore its safety and efficacy.
Read more →ACIUAC Immune Reports Interim Safety Data From Phase 1b 2 ABATE Trial of ACI 24 060 in Down Syndrome
AC Immune Reports Interim Safety Data From Phase 1b 2 ABATE Trial of ACI 24 060 in Down Syndrome
Read more →ACIU▲ +13.4%on this news
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody
AC Immune SA reported positive interim results from their Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The interim data demonstrated a favorable safety profile and strong immunogenicity, with an induced increase in anti-alpha-synuclein antibodies. CEO Dr. Andrea Pfeifer expressed optimism, highlighting plans to advance the study into Part 2 in H1 2025, including evaluations of disease progression and biomarker identification. The findings underscore the potential of active immunotherapy in combating neurodegenerative diseases.
Read more →ACIU▲ +13.4%on this news
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI 7104 056 Active Immunotherapy in Early Parkinson s Disease
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI 7104 056 Active Immunotherapy in Early Parkinson s Disease
Read more →ACIUAC Immune to Present at The Jefferies 2024 London Healthcare Conference
AC Immune to Present at The Jefferies 2024 London Healthcare Conference
Read more →ACIU▲ +10.2%on this news
Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 2,736 3,376 Right-of-use assets 6 3,091 3,508
AC Immune SA reported its interim financial results for the third quarter of 2024, highlighting a total asset increase to 244,248 CHF thousands, up from 182,814 CHF thousands in the previous period. Despite an increase in total revenue driven by contract revenues, the company recorded an operating loss for the quarter. Accumulated losses also rose substantially, and cash reserves showed a significant decline compared to the end of 2023. The financial data reflects both opportunities for revenue growth and notable challenges in expense management and loss accumulation.
Read more →ACIU▲ +10.2%on this news
AC Immune Reports Third Quarter 2024 Financial Results And Provides a Corporate Update
AC Immune Reports Third Quarter 2024 Financial Results And Provides a Corporate Update
Read more →ACIU▲ +5.8%on this news
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Re ain Trial of ACI-35.030 in Preclinical Alzheimer's Disease Prescreening rate of Phase 2b Re ain trial triggers clinical developm
AC Immune SA has announced that it will receive a second milestone payment of CHF 24.6 million due to the rapid prescreening rate in the Phase 2b Re-Ain trial for ACI-35.030, now named JNJ-2056, aimed at treating preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The drug has received Fast Track designation from the FDA, signifying its potential value for patients. The trial is being conducted at over 40 sites worldwide, assessing JNJ-2056's effects on cognitive decline and Tau pathology.
Read more →ACIU▲ +5.8%on this news
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Retain Trial of ACI 35 030 in Preclinical Alzheimer s Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Retain Trial of ACI 35 030 in Preclinical Alzheimer s Disease
Read more →ACIUAC Immune s Pi 2620 Tau PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
AC Immune s Pi 2620 Tau PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
Read more →ACIUAC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer's disease by AC Immune's partner, LMI T
AC Immune announced that its partner Life Molecular Imaging has received Fast Track Designation from the FDA for the Tau-PET diagnostic, PI-2620, targeting Alzheimer's disease and other neurodegenerative conditions. This designation aims to accelerate development and review processes for crucial diagnostics. PI-2620 is currently in Phase 3 trials and has shown potential for accurately imaging Tau pathology, which could lead to improved diagnosis and treatment of various neurodegenerative diseases. The company aims for this designation to enhance precision prevention efforts in clinical settings.
Read more →ACIUAC Immune Reports Second Quarter 2024 Financial Results And Provides a Corporate Update
AC Immune Reports Second Quarter 2024 Financial Results And Provides a Corporate Update
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 2,926 3,376 Right-of-use assets 6 3,235 3,508 Inta
The article presents unaudited condensed consolidated balance sheets for ACIU as of June 30, 2024, and December 31, 2023. It outlines the company's non-current assets, including property, plant and equipment, right-of-use assets, and intangible assets. Additionally, it provides details on current assets like prepaid expenses and accrued income. These financial statements are critical for stakeholders interested in ACIU's financial position.
Read more →ACIUAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morph
AC Immune SA has unveiled its novel morADC (Morphomer Antibody Drug Conjugate) technology aimed at improving treatment for neurodegenerative diseases at the AAIC 2024 conference. This innovative technology synergizes the capabilities of its SupraAntigen and Morphomer platforms, potentially offering significant advancements in delivering therapeutic candidates. The company aims to address challenges in existing treatment modalities, showcasing confidence in their ability to enhance clinical outcomes. With multiple therapeutic programs in development, AC Immune positions itself as a leader in precision medicine for neurodegenerative diseases.
Read more →ACIUAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate Adc Technology For Improved Efficacy in Neurodegenerative Diseases at Aaic 2024
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate Adc Technology For Improved Efficacy in Neurodegenerative Diseases at Aaic 2024
Read more →ACIU▲ +10.8%on this news
AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is ful
AC Immune's candidate ACI-35.030, now renamed JNJ-2056, has received Fast Track designation from the FDA for its use in treating preclinical Alzheimer's disease. This designation facilitates more efficient development and regulatory review due to the drug's innovative approach in targeting the phosphorylated Tau protein. The ongoing Phase 2b ReTain trial marks a significant milestone, being the first clinical study of active immunotherapy in cognitively healthy individuals with preclinical Alzheimer's. The trial aims to assess whether JNJ-2056 can delay the onset of cognitive impairment by inhibiting pathological Tau spread.
Read more →ACIU▲ +10.8%on this news
AC Immune s ACI 35 030 Now Jnj 2056 Granted FDA Fast Track Designation For Alzheimer s Disease
AC Immune s ACI 35 030 Now Jnj 2056 Granted FDA Fast Track Designation For Alzheimer s Disease
Read more →ACIU▲ +5.1%on this news
AC Immune Showcasing Its Novel Morphomer Antibody Drug Conjugate Moradc Platform For The Treatment of Neurodegenerative Diseases at Aaic 2024
AC Immune Showcasing Its Novel Morphomer Antibody Drug Conjugate Moradc Platform For The Treatment of Neurodegenerative Diseases at Aaic 2024
Read more →ACIUNASDAQ: ACIU | AGM Presentation, June 2024 2024 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute "forward - looking statements" within the meanin
AC Immune is set to provide an update on its business strategies and pipeline during its Annual General Meeting on June 20, 2024. The company aims to pioneer precision medicine for neurodegenerative diseases, highlighting a broad pipeline that includes both active immunotherapy programs and promising partnerships. Notably, the collaboration with Takeda for their ACI-24.060 therapy involves substantial upfront payments and the possibility of significant milestone revenues. The company's focus on innovative therapies suggests a strong outlook for future growth.
Read more →ACIU▲ +9.3%on this news· ran to +31% by day 3
AC Immune to Present at The Jefferies Global Healthcare Conference in June 2024
AC Immune to Present at The Jefferies Global Healthcare Conference in June 2024
Read more →ACIU▲ +5.7%on this news
to the Company's Form 6 - K on 14 March 2024 can be downloaded from the Company's website: ir.acimmune.com/sec - filings . It explains the governance framework and the principles underlying the compensation structure at
AC Immune SA is preparing for its Annual General Meeting on June 20, 2024, where it will present its 2023 financial statements and progress in neurodegenerative disease therapies. The company highlights a strategic focus on precision medicine and recent advancements in its pipeline, including a landmark partnership with Takeda potentially valued at over $2 billion. Key innovations include a Phase 2b trial for ACI-35.030 and ongoing development of imaging agents for disease diagnosis. Overall, AC Immune is positioned for significant growth and innovation in the treatment of Alzheimer's and Parkinson's diseases.
Read more →ACIU▲ +42.9%on this news· ran to +55% by day 1
AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer s Disease
AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer s Disease
Read more →ACIU▲ +42.9%on this news· ran to +55% by day 1
AC Immune Reports First Quarter 2024 Financial Results And Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results And Provides a Corporate Update
Read more →ACIU▲ +42.9%on this news· ran to +55% by day 1
Bettter Health, Brighter Future News Release AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to
AC Immune and Takeda have entered into an exclusive option and license agreement for the immunotherapy candidate ACI-24.060, targeting amyloid beta for Alzheimer's disease. This agreement allows AC Immune to leverage Takeda's expertise and resources while retaining responsibility for the ongoing Phase 1b/2 trial. Following the option exercise, Takeda will fund further clinical development and commercialization efforts. The partnership highlights potential advancements in treating Alzheimer's and involves substantial financial incentives for AC Immune.
Read more →ACIU▲ +42.9%on this news· ran to +55% by day 1
Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 3,236 3,376 Right-of-use assets 6 3,341 3,508 Int
AC Immune SA released its unaudited interim consolidated financial statements for the three months ended March 31, 2024. The company reported an increase in accumulated losses and a higher operating loss than the previous year. Additionally, cash and cash equivalents saw a notable decline, potentially indicating liquidity challenges. Overall, the financial performance reflects ongoing difficulties in the company's operations.
Read more →ACIU▼ -10%on this news
AC Immune Reports Full Year 2023 Financial Results And Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results And Provides a Corporate Update
Read more →ACIU▼ -10%on this news
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkin
AC Immune SA reported its financial results for 2023, highlighting advancements in its Phase 2 clinical trials targeting Alzheimer's and Parkinson's diseases. The company's CEO emphasized several expected milestones in 2024, including significant updates on their ACI-24.060 program related to amyloid plaque reduction. Additionally, the financial report indicated an increase in operating expenses and continued operating losses, despite a substantial rise in contract revenue. The firm is strategically positioned with strong partnerships aimed at enhancing its financial outlook and supporting ongoing developments.
Read more →ACIUAC Immune Announces Upcoming Presentations at AD PD 2024
AC Immune Announces Upcoming Presentations at AD PD 2024
Read more →ACIUAC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to
AC Immune announced the regaining of global rights to its investigational antibodies crenezumab and semorinemab after terminating collaboration agreements with Genentech and Roche. The company's strategy emphasizes progressing its three active immunotherapy candidates in Phase 2 trials focused on Alzheimer’s disease. While crenezumab has demonstrated a strong safety profile, semorinemab did not meet its primary efficacy endpoint in earlier studies. The final results from the Lauriet trial are still awaited, which may influence future developments.
Read more →ACIUAC Immune to Regain Global Rights to Crenezumab And Semorinemab
AC Immune to Regain Global Rights to Crenezumab And Semorinemab
Read more →ACIUAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is ex
AC Immune SA has announced positive progress in its clinical pipeline focusing on Alzheimer's and Parkinson's diseases. The company has successfully completed enrollment for two cohorts in the Phase 1b/2 trial of its ACI-24.060 immunotherapy and reports encouraging safety and immunogenicity data. Additionally, AC Immune strengthened its financial position with a $50 million equity offering and expects two milestone payments from a partnered trial. The company aims to continue advancing its novel immunotherapies into 2024 and beyond.
Read more →ACIUAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline For Alzheimer s And Parkinson Diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline For Alzheimer s And Parkinson Diseases
Read more →ACIU▲ +5.7%on this news
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on c
AC Immune has announced the advancement of its targeted anti-pTau active immunotherapy, ACI-35.030, into a Phase 2b trial aimed at treating preclinical Alzheimer's disease. This trial, dubbed ReTain, will investigate the therapy's effects on delaying or preventing cognitive symptoms related to Alzheimer's. Following positive results from earlier trials, AC Immune will receive milestone payments from its partnership with Janssen Pharmaceuticals as the study progresses. The therapy is designed to activate the immune system against pathological Tau, a key player in Alzheimer’s disease progression.
Read more →ACIU▲ +5.7%on this news
AC Immune s Targeted Anti Ptau Active Immunotherapy For Alzheimer s Disease Advances Into Phase 2b Trial
AC Immune s Targeted Anti Ptau Active Immunotherapy For Alzheimer s Disease Advances Into Phase 2b Trial
Read more →ACIU▲ +5.7%on this news
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares
Read more →ACIUAC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO Retiring CSO Dr. Marie Kosco-
AC Immune has announced the strengthening of its management team with the appointment of Dr. Madiha Derouazi as Chief Scientific Officer and Christopher Roberts as Chief Financial Officer, effective January 1, 2024. Dr. Derouazi brings a wealth of experience from her previous roles, including CEO of Speransa Therapeutics and founder of AMAL Therapeutics. The transition follows the retirement of former CSO Dr. Marie Kosco-Vilbois, who will continue to support the company as an expert consultant. This change is viewed as a strategic move to enhance AC Immune's potential in the field of precision medicine for neurodegenerative diseases.
Read more →ACIUAC Immune Strengthens Management Appoints Madiha Derouazi As Cso And Christopher Roberts As CFO
AC Immune Strengthens Management Appoints Madiha Derouazi As Cso And Christopher Roberts As CFO
Read more →ACIUAC Immune to Present at The Jefferies 2023 London Healthcare Conference
AC Immune to Present at The Jefferies 2023 London Healthcare Conference
Read more →ACIUAC Immune Reports Third Quarter 2023 Financial Results And Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results And Provides a Corporate Update
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 3,627 4,259 Right-of-use assets 6 2,403 2,808
AC Immune SA reported its Interim Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2023. The company experienced a significant increase in operating loss to CHF 15,140 and did not generate any revenue in the current reporting period, compared to CHF 3,934 in the previous year. Additionally, total current assets declined notably, and accumulated losses rose to CHF 310,488. The financial performance suggests ongoing challenges for the company as it navigates its business strategy in the biopharmaceutical sector.
Read more →ACIUAC Immune to Host Kol Webinar on Amyloid Plaque PET Imaging in Alzheimer s Disease As a Surrogate of Clinical Efficacy on November 9 2023
AC Immune to Host Kol Webinar on Amyloid Plaque PET Imaging in Alzheimer s Disease As a Surrogate of Clinical Efficacy on November 9 2023
Read more →ACIU▼ -6.6%on this news
AC Immune Clinical Data Published in Nature Communications Show Alpha Synuclein PET Tracer ACI 12589 Has Potential As Neurodegenerative Disease Diagnostic
AC Immune Clinical Data Published in Nature Communications Show Alpha Synuclein PET Tracer ACI 12589 Has Potential As Neurodegenerative Disease Diagnostic
Read more →ACIUAC Immune Announces Upcoming Presentations at The 16th Ctad Conference
AC Immune Announces Upcoming Presentations at The 16th Ctad Conference
Read more →ACIUAC Immune to Present at The Jefferies 2023 Cns Neuro Summit in October 2023
AC Immune to Present at The Jefferies 2023 Cns Neuro Summit in October 2023
Read more →ACIUAC Immune to Present at The H C Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at The H C Wainwright 25th Annual Global Investment Conference in September 2023
Read more →ACIUAC Immune Reports Second Quarter 2023 Financial Results And Provides a Corporate Update
AC Immune Reports Second Quarter 2023 Financial Results And Provides a Corporate Update
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ ​ ​ June 30, &
AC Immune SA's interim financial statements as of June 30, 2023, reveal a continued trend of significant losses, with a reported loss of 34.3 million CHF for the first half of the year. The company's total assets have decreased from the end of 2022, reflecting financial challenges. While some current assets, including cash and equivalents, have increased, the overall financial health appears strained due to accumulating losses and rising liabilities. Despite its focus on neurodegenerative disease treatments, the financial outlook raises concerns for stakeholders.
Read more →ACIUAC Immune to Present at The Btig Virtual Biotechnology Conference 2023
AC Immune to Present at The Btig Virtual Biotechnology Conference 2023
Read more →ACIUAC Immune SA Appoints New Chief Medical Officer
AC Immune SA Appoints New Chief Medical Officer
Read more →ACIUAC Immune SA Appoints New Chief Medical Officer Nuno Mendon a, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland
AC Immune SA has appointed Nuno Mendon a, MD, as the new Chief Medical Officer effective October 1st. He will also join the Executive Committee, succeeding Johannes Streffer, MD. Dr. Mendon a brings significant experience in the clinical development of therapeutics for neurodegenerative diseases, having held senior roles at various pharmaceutical companies. The company is optimistic about his leadership in advancing its ongoing clinical development programs and innovative technology platforms.
Read more →ACIUAC Immune Showcasing Precision Medicine Programs at Aaic 2023
AC Immune Showcasing Precision Medicine Programs at Aaic 2023
Read more →ACIU▲ +71.7%on this news
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA
AC Immune SA has announced the granting of Fast Track designation from the FDA for its anti-amyloid-beta immunotherapy candidate, ACI-24.060, intended for treating Alzheimer's disease. This designation facilitates expedited development and review, while the ongoing Phase 1b/2 ABATE study is expanding into the United States, having already dosed its first participant with Down syndrome. The company's CEO emphasized the program's potential to target toxic Abeta species effectively, which could lead to significant advantages over current monoclonal antibody therapies. Further interim safety and immunogenicity data are expected later this year, with an interim readout of imaging data anticipated in early 2024.
Read more →ACIU▲ +71.7%on this news
AC Immune Receives FDA Fast Track Designation For Anti Amyloid Beta Active Immunotherapy ACI 24 060 to Treat Alzheimer s Disease
AC Immune Receives FDA Fast Track Designation For Anti Amyloid Beta Active Immunotherapy ACI 24 060 to Treat Alzheimer s Disease
Read more →ACIUAC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders
Read more →ACIUNASDAQ: ACIU | AGM Presentation, June 2023 2023 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting
AC Immune's annual general meeting highlighted its advancements in precision medicine specific to neurodegenerative diseases. The company presented a robust pipeline consisting of 16 programs, including critical Phase 3 and Phase 2 studies. They emphasized their focus on delivering innovative therapies, particularly in Alzheimer's disease, while maintaining a strong balance sheet that supports funding through Q3 2024. However, they acknowledged potential risks related to COVID-19 and the uncertainties intrinsic to their forward-looking statements.
Read more →ACIUto the Company's Form 6 - K on 16 March 2023 can be downloaded from the Company's website: https://ir.acimmune.com/sec - filings It explains the governance framework and the principles underlying the compensation structu
AC Immune SA announced the upcoming Annual General Meeting (AGM) scheduled for June 23, 2023. The company aims to highlight its progress in developing vaccines for Alzheimer's disease and Parkinson's disease, supported by positive Phase 1b/2a data. AC Immune plans to submit a U.S. Investigational New Drug application for expanding clinical trials and is optimistic about the future, projecting significant milestones in its research initiatives. The company is also set to approve its 2022 financial statements and compensation report during the AGM.
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 4,011 4,259 Right-of-use assets 6 2,674 2,808 Int
AC Immune SA reported its interim consolidated financial results for the first quarter of 2023, showing a net loss of CHF 17,513,000, a slight improvement from the CHF 18,848,000 loss reported in the same quarter of 2022. The company experienced a decrease in total assets and an increase in accumulated losses, which reached CHF 280,105,000 as of March 31, 2023. Despite a higher cash balance of CHF 57,434,000 compared to December 2022, current liabilities and operating expenses remain significant concerns. Overall, the financial statements reflect ongoing challenges as the company continues its operations in developing treatments for neurodegenerative diseases.
Read more →ACIUAC Immune Reports First Quarter 2023 Financial Results And Provides a Corporate Update
AC Immune Reports First Quarter 2023 Financial Results And Provides a Corporate Update
Read more →ACIUAC Immune to Host Key Opinion Leader Webinar on Early Diagnosis And Prevention of Alzheimer s Disease
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis And Prevention of Alzheimer s Disease
Read more →ACIUAC Immune at AD PD 2023 to Present New Clinical And Preclinical Data From Its Precision Medicine Pipeline
AC Immune at AD PD 2023 to Present New Clinical And Preclinical Data From Its Precision Medicine Pipeline
Read more →ACIUAC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are al
AC Immune SA reported its financial results for 2022, reflecting a significant operational loss. Despite the financial challenges, the company is making noteworthy progress in its clinical-stage vaccine programs targeting neurodegenerative diseases, such as Alzheimer's and Parkinson's. Upcoming milestones include interim readouts and the initiation of new cohorts in clinical studies. Additionally, AC Immune is seeking to expand its research capabilities into the United States, highlighting potential growth opportunities.
Read more →ACIUAC Immune Reports Full Year 2022 Financial Results And Provides Corporate Update
AC Immune Reports Full Year 2022 Financial Results And Provides Corporate Update
Read more →ACIUAC Immune to Report Full Year 2022 Financial Results And Provide Corporate Update on March 16 2023
AC Immune to Report Full Year 2022 Financial Results And Provide Corporate Update on March 16 2023
Read more →ACIUAC Immune Awarded New Grants From Mjff And Target ALS Supporting Programs Targeting TDP 43
AC Immune Awarded New Grants From Mjff And Target ALS Supporting Programs Targeting TDP 43
Read more →ACIUAC Immune to Present at The Svb Securities Global Biopharma Conference
AC Immune to Present at The Svb Securities Global Biopharma Conference
Read more →ACIUAC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABA
AC Immune announced promising interim safety and immunogenicity results for its anti-amyloid beta vaccine, ACI-24.060, in the Phase 1b/2 ABATE trial targeting Alzheimer’s disease. The vaccine was well tolerated, prompting the initiation of higher dose cohorts and the inclusion of participants with Down syndrome. Future data on amyloid plaque reduction is expected in 2024. AC Immune aims to address significant medical needs with this novel therapeutic approach.
Read more →ACIUAC Immune s ACI 24 060 Anti Amyloid Beta Vaccine For Alzheimer s Shows Positive Initial Interim Safety And Immunogenicity in Phase 1b 2 ABATE Trial
AC Immune s ACI 24 060 Anti Amyloid Beta Vaccine For Alzheimer s Shows Positive Initial Interim Safety And Immunogenicity in Phase 1b 2 ABATE Trial
Read more →ACIUAC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic Pi 2620 For Alzheimer s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic Pi 2620 For Alzheimer s Disease
Read more →ACIUAC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidate Based on this
AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development Lausanne, Switzerland, November 30, 2022 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today
Read more →ACIUAC Immune s Alzheimer s Disease Vaccine Candidate ACI 35 030 Selected For Further Development
AC Immune s Alzheimer s Disease Vaccine Candidate ACI 35 030 Selected For Further Development
Read more →ACIUAC Immune to Present Progress of Alzheimer s Disease Programs Targeting Abeta And Tau at The 15th Ctad Conference
AC Immune to Present Progress of Alzheimer s Disease Programs Targeting Abeta And Tau at The 15th Ctad Conference
Read more →ACIU▼ -5%on this news
AC Immune to Present at The Jefferies London Healthcare Conference
AC Immune to Present at The Jefferies London Healthcare Conference
Read more →ACIU▼ -6.6%on this news
Condensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, ​ As of December 31, Bala
83590948728879670.160.220.160.220.620.7183537655726386980.620.7100016516252022-09-30Q32022--12-316-KAC IMMUNE SAfalse Condensed Consolidated Balance Sheets (Unaudited) As of September 30, As of December 31, Balance Sheets Notes 2022 2021 ASSETS Non-current assets
Read more →ACIU▼ -6.6%on this news
AC Immune Reports Third Quarter 2022 Financial Results And Provides a Corporate Update
AC Immune Reports Third Quarter 2022 Financial Results And Provides a Corporate Update
Read more →ACIUAC Immune Opens New Centers in Phase 1b 2 Trial Evaluating ACI 24 Targeting Abeta in Alzheimer s Disease And Down Syndrome
AC Immune Opens New Centers in Phase 1b 2 Trial Evaluating ACI 24 Targeting Abeta in Alzheimer s Disease And Down Syndrome
Read more →ACIUAC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease AC Immune's Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer's Di
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease Lausanne, Switzerland, September 26, 2022 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative di
Read more →ACIUAC Immune Partner Lmi Progresses Tau PET Tracer Pi 2620 Into Late Stage Development in Alzheimer s Disease
AC Immune Partner Lmi Progresses Tau PET Tracer Pi 2620 Into Late Stage Development in Alzheimer s Disease
Read more →ACIUAC Immune Receives a Grant From The Michael J Fox Foundation For Continued Development of Parkinson s Disease Diagnostic Imaging Agent
AC Immune Receives a Grant From The Michael J Fox Foundation For Continued Development of Parkinson s Disease Diagnostic Imaging Agent
Read more →ACIUAC Immune Kol Webinar on The Potential Benefits of Vaccines For Alzheimer s And Parkinson s Diseases
AC Immune Kol Webinar on The Potential Benefits of Vaccines For Alzheimer s And Parkinson s Diseases
Read more →ACIU▼ -5.5%on this news
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat And Prevent Alzheimer s And Parkinson s Diseases
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat And Prevent Alzheimer s And Parkinson s Diseases
Read more →ACIUDetailed data from the phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC Crenezumab was safe and well tolerated with no cases of ARIA-E
Detailed data from the phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC Lausanne, Switzerland, August 2, 2022 -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision
Read more →ACIUDetailed Data From The Phase Ii Crenezumab Alzheimer s Prevention Initiative Study in Autosomal Dominant Alzheimer s Disease Presented at Aaic
Detailed Data From The Phase Ii Crenezumab Alzheimer s Prevention Initiative Study in Autosomal Dominant Alzheimer s Disease Presented at Aaic
Read more →ACIUAC Immune Reports Second Quarter 2022 Financial Results And Provides Corporate Update
AC Immune Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Read more →ACIUCondensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) Balance Sheets Notes As of
Condensed Consolidated Balance Sheets (Unaudited) Balance Sheets Notes As of June 30, 2022 As of December 31, 2021 ASSETS Non-current assets Property, plant and equipment 5 4,997 5,116 Right-of-use assets 6 2,632 2,914 Intangible asset 9 5
Read more →ACIUAC Immune Announces Upcoming Presentations at The Alzheimer s Association International Conference
AC Immune Announces Upcoming Presentations at The Alzheimer s Association International Conference
Read more →ACIUNASDAQ: ACIU | Annual General Meeting, June 2022 2022 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting
NASDAQ: ACIU | Annual General Meeting, June 2022 2022 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting, June 24, 2022 www.acimmune.com NASDAQ: ACIU | Annual General Meeting, June
Read more →ACIU▼ -17.8%on this news
AC Immune Provides Update on Alzheimer s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer s Disease
AC Immune Provides Update on Alzheimer s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer s Disease
Read more →ACIU▼ -17.8%on this news
AC Immune provides update on Alzheimer's Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer's disease Crenezumab did not statistically significantly slow or prevent cognitive
AC Immune provides update on Alzheimer's Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer's disease Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-o
Read more →ACIUAC Immune to Present at The 2022 Jefferies Healthcare Conference
AC Immune to Present at The 2022 Jefferies Healthcare Conference
Read more →ACIUto the Company's Form 6 - K on 22 March 2022 can be downloaded from the Company's website: https://ir.acimmune.com/sec - filings It explains the governance framework and the principles underlying the compensation structu
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA Date Friday, 24 June 2022 | 2 :30pm CEST | 8:30am EDT 1 Contents 3 Letter to Shareholders 5 Agenda and proposals 12 Organizational notes 15 Say on Pay Shareholder information on compensation proposal
Read more →ACIUAC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
Read more →ACIU▼ -12.3%on this news
AC Immune s Anti Abeta Vaccine Results From Phase 1b Study in Down Syndrome Published in Jama Neurology
AC Immune s Anti Abeta Vaccine Results From Phase 1b Study in Down Syndrome Published in Jama Neurology
Read more →ACIUAC Immune Reports First Quarter 2022 Financial Results And Provides Corporate Update
AC Immune Reports First Quarter 2022 Financial Results And Provides Corporate Update
Read more →ACIU▼ -6.2%on this newsshared move
AC Immune to Present at The B Riley Annual Neuro Ophthalmology Virtual Investor Conference
AC Immune to Present at The B Riley Annual Neuro Ophthalmology Virtual Investor Conference
Read more →ACIU▼ -6.8%on this news
AC Immune Reports Changes to Senior Management
AC Immune Reports Changes to Senior Management
Read more →ACIU▼ -6.5%on this news
AC Immune Kol Webinar on First Clinical Proof of Concept For Alpha Synuclein Diagnostic Shows Breakthrough Potential For Neurodegenerative Diseases
AC Immune Kol Webinar on First Clinical Proof of Concept For Alpha Synuclein Diagnostic Shows Breakthrough Potential For Neurodegenerative Diseases
Read more →ACIUAC Immune Reports Full Year 2021 Financial Results And Provides Corporate Update
AC Immune Reports Full Year 2021 Financial Results And Provides Corporate Update
Read more →ACIUAC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Sem
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expecte
Read more →ACIUAC Immune to Host Key Opinion Leader Webinar on Alpha Synuclein As a Target in Neurodegenerative Diseases
AC Immune to Host Key Opinion Leader Webinar on Alpha Synuclein As a Target in Neurodegenerative Diseases
Read more →ACIUAC Immune Reports First Live Images of Alpha Synuclein in Human Brain With New PET Tracer For Neurodegenerative Disease at AD Pdtm Conference
AC Immune Reports First Live Images of Alpha Synuclein in Human Brain With New PET Tracer For Neurodegenerative Disease at AD Pdtm Conference
Read more →ACIUAC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PD TM Conference ACI-12589 distinguished multiple system atrophy (MSA) from othe
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be d
Read more →ACIUAC Immune to Present at The AD PD 2022 New Clinical And Preclinical Data For Alpha Synuclein Abeta And TDP 43 Programs
AC Immune to Present at The AD PD 2022 New Clinical And Preclinical Data For Alpha Synuclein Abeta And TDP 43 Programs
Read more →ACIUAC Immune ACI 35 030 Phase 1b 2a Trial Interim Data Confirm Consistent Safety And Potent Immunogenicity of Ptau Alzheimer s Vaccine in High Dose Cohort
AC Immune ACI 35 030 Phase 1b 2a Trial Interim Data Confirm Consistent Safety And Potent Immunogenicity of Ptau Alzheimer s Vaccine in High Dose Cohort
Read more →ACIUAC Immune ACI 24 Data in Brain Communications Show Abeta Vaccine Candidate Induces Immunity Against Pyroglu Abeta Key Driver of Alzheimer s Disease
AC Immune ACI 24 Data in Brain Communications Show Abeta Vaccine Candidate Induces Immunity Against Pyroglu Abeta Key Driver of Alzheimer s Disease
Read more →ACIUAC Immune to Present at The Svb Leerink 11th Annual Global Healthcare Conference
AC Immune to Present at The Svb Leerink 11th Annual Global Healthcare Conference
Read more →ACIUAC Immune Awarded Two Michael J Fox Foundation Grants to Advance Small Molecule Parkinson s Disease Programs
AC Immune Awarded Two Michael J Fox Foundation Grants to Advance Small Molecule Parkinson s Disease Programs
Read more →ACIUAC Immune Announces Interim Phase 1b 2a Data Showing That Its ACI 35 030 Anti Ptau Alzheimer s Vaccine Generates a Potent Immune Response
AC Immune Announces Interim Phase 1b 2a Data Showing That Its ACI 35 030 Anti Ptau Alzheimer s Vaccine Generates a Potent Immune Response
Read more →ACIUAC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response Observed strong induction of antibodies specific for pathological fo
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD
Read more →ACIU▼ -19.2%on this newsshared move
AC Immune Announces Late Breaker Presentation By Genentech at Ctad on Phase 2 Lauriet Study of Semorinemab in Mild to Moderate Alzheimer s Disease
AC Immune Announces Late Breaker Presentation By Genentech at Ctad on Phase 2 Lauriet Study of Semorinemab in Mild to Moderate Alzheimer s Disease
Read more →ACIUAC Immune Reports Third Quarter 2021 Financial Results And Provides Corporate Update
AC Immune Reports Third Quarter 2021 Financial Results And Provides Corporate Update
Read more →ACIUAC Immune Extends Research Collaboration With University of Pennsylvania Focusing on The Pathogenic Protein TDP 43 a Major Driver of Neurodegenerative Diseases
AC Immune Extends Research Collaboration With University of Pennsylvania Focusing on The Pathogenic Protein TDP 43 a Major Driver of Neurodegenerative Diseases
Read more →ACIU▲ +6.1%on this newsshared move
New Data on AC Immune s Abeta And Ptau Clinical Programs in Alzheimer s Disease to Be Presented at Ctad 2021
New Data on AC Immune s Abeta And Ptau Clinical Programs in Alzheimer s Disease to Be Presented at Ctad 2021
Read more →ACIUAC Immune Holds Its Extraordinary General Meeting And Appoints Monica Shaw M D And Prof Monika B%c3%bctler Dr Oec to Its Board of Directors
AC Immune Holds Its Extraordinary General Meeting And Appoints Monica Shaw M D And Prof Monika B%c3%bctler Dr Oec to Its Board of Directors
Read more →ACIUAC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika B tler, Dr. oec., to its Board of Directors Dr. Shaw is a pharmaceutical industry expert who has been invol
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika B tler, Dr. oec., to its Board of Directors Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human
Read more →ACIUNotice of the Extraordinary General Meeting (EGM) of 29 October 2021 To the Shareholders of AC Immune SA 1 Date Friday, 29 October 2021 | 11:00 AM CEST Contents 4 Letter to Shareholders 5 Agenda and proposals 12 Organiza
Notice of the Extraordinary General Meeting (EGM) of 29 October 2021 To the Shareholders of AC Immune SA 1 Date Friday, 29 October 2021 | 11:00 AM CEST Contents 4 Letter to Shareholders 5 Agenda and proposals 12 Organizational notes 3 Dear Shareholders, We are pleased to welco
Read more →ACIUAC Immune CEO Andrea Pfeifer Receives First Sef Womenaward For CEO of The Year
AC Immune CEO Andrea Pfeifer Receives First Sef Womenaward For CEO of The Year
Read more →ACIUAC Immune to Participate in Upcoming Virtual Investor Conferences in September
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
Read more →ACIU▲ +16.3%on this newsshared move
AC Immune Announces First Positive Cognitive Results For a Tau Targeting Monoclonal Antibody in Alzheimer s Disease
AC Immune Announces First Positive Cognitive Results For a Tau Targeting Monoclonal Antibody in Alzheimer s Disease
Read more →ACIU▲ +16.3%on this newsshared move
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a sta
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, AD
Read more →ACIUAC Immune Reports Second Quarter 2021 Financial Results And Provides Corporate Update
AC Immune Reports Second Quarter 2021 Financial Results And Provides Corporate Update
Read more →ACIUAC Immune Presents Full Phase 1b Results on Anti Abeta Vaccine And Discusses Its First in Class Diagnostic For Parkinson s Disease at Aaic 2021
AC Immune Presents Full Phase 1b Results on Anti Abeta Vaccine And Discusses Its First in Class Diagnostic For Parkinson s Disease at Aaic 2021
Read more →ACIUAC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH All-stock transaction maintains AC Immune's strong cash position USD 25
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH All-stock transaction maintains AC Immune's strong cash position USD 25 million private placement led by premier investor Athos
Read more →ACIUNASDAQ: ACIU | Annual General Meeting 2021 2021 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting |
NASDAQ: ACIU | Annual General Meeting 2021 2021 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting | June 25, 2021 www.acimmune.com Version: 22.06.2021 NASDAQ: ACIU | Annual General
Read more →ACIUAC Immune Holds Its Annual General Meeting of Shareholders
AC Immune Holds Its Annual General Meeting of Shareholders
Read more →ACIUAC Immune Provides Update on Alzheimer s Disease Vaccine Candidates Targeting Pathological Amyloid Beta
AC Immune Provides Update on Alzheimer s Disease Vaccine Candidates Targeting Pathological Amyloid Beta
Read more →ACIUNotice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1 Date Friday
Notice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1 Date Friday, June 25, 2021 | 11:00am CET Contents 4 Letter to Shareholders 6 Overview 7 Agenda and proposals 16 Organizational notes 19 Say on Pay Shareholder information on compensation proposal 3
Read more →ACIUAC Immune to Highlight First in Class Alzheimer s Disease Vaccine Programs at Upcoming Investor Conferences
AC Immune to Highlight First in Class Alzheimer s Disease Vaccine Programs at Upcoming Investor Conferences
Read more →ACIUAC Immune Announces Expansion of Phase 1b 2a Phospho Tau Alzheimer s Vaccine Trial And Provides a Program Update
AC Immune Announces Expansion of Phase 1b 2a Phospho Tau Alzheimer s Vaccine Trial And Provides a Program Update
Read more →ACIUAC Immune SA Balance Sheets (in CHF thousands) Notes As of
Notes As of March 31, 2021 As of December 31, 2020 ASSETS Non-current assets Property, plant and equipment 5 4,896 4,416 Right-of-use assets 6 2,147 2,223 Long-term accrued income 3 93 - Long-term financial assets 8 334 334 Tota
Read more →ACIUAC Immune Reports First Quarter 2021 Financial Results And Provides Corporate Update
AC Immune Reports First Quarter 2021 Financial Results And Provides Corporate Update
Read more →ACIUAC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investme
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova In
Read more →ACIUAC Immune Hosts Investor Webinar Highlighting The Power of Its Morphomer Platform to Enable Precision Medicine For Neurodegenerative Disease
AC Immune Hosts Investor Webinar Highlighting The Power of Its Morphomer Platform to Enable Precision Medicine For Neurodegenerative Disease
Read more →ACIUAC Immune Appoints Experienced Biotech And Investment Executive Dr Alan Colowick to Board of Directors
AC Immune Appoints Experienced Biotech And Investment Executive Dr Alan Colowick to Board of Directors
Read more →ACIUAC Immune to Host Webinar Highlighting Its Innovative Morphomer Technology Platform And Pipeline
AC Immune to Host Webinar Highlighting Its Innovative Morphomer Technology Platform And Pipeline
Read more →ACIUAC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook Anti-pTau Alzheimer's vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development int
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook Lausanne, Switzerland, March 23, 2021 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its fi
Read more →ACIUAC Immune Reports Full Year 2020 Financial Results And Provides 2021 R D Outlook
AC Immune Reports Full Year 2020 Financial Results And Provides 2021 R D Outlook
Read more →ACIUAC Immune Announces New Clinical Results in Down Syndrome And Plans For Future Development of Anti Amyloid Beta Vaccine
AC Immune Announces New Clinical Results in Down Syndrome And Plans For Future Development of Anti Amyloid Beta Vaccine
Read more →ACIUAC Immune Presents New Preclinical Data For Therapeutic And Diagnostic Candidates Addressing Novel Targets For Neurodegenerative Diseases
AC Immune Presents New Preclinical Data For Therapeutic And Diagnostic Candidates Addressing Novel Targets For Neurodegenerative Diseases
Read more →ACIULausanne, 26 February 2021 Invitation to the Extraordinary Shareholders' Meeting Date: Wednesday, 31 March 2021 | 2:00 PM Central European Time Place: EPFL Innovation Park, Building B | 1015 Lausanne | Switzerland I. For
Lausanne, 26 February 2021 the Extraordinary Shareholders' Meeting Date: Wednesday, 31 March 2021 | 2:00 PM Central European Time Place: EPFL Innovation Park, Building B | 1015 Lausanne | Switzerland I. Foreword 2 II. Agenda 4 1. Election of new Director 4 2. Amendments of th
Read more →ACIUAC Immune to Present New Data From Alpha Synuclein And TDP 43 Programs at The AD PD 2021 Virtual Conference
AC Immune to Present New Data From Alpha Synuclein And TDP 43 Programs at The AD PD 2021 Virtual Conference
Read more →ACIUAC Immune to Highlight Promising Alzheimer s Vaccine at The Svb Leerink 10th Annual Global Healthcare Conference
AC Immune to Highlight Promising Alzheimer s Vaccine at The Svb Leerink 10th Annual Global Healthcare Conference
Read more →ACIUAC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially t
AC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's ACI
Read more →ACIUAC Immune s Alzheimer s Vaccine Generates Potent Anti Ptau Antibody Response in a Phase 1b 2a Study
AC Immune s Alzheimer s Vaccine Generates Potent Anti Ptau Antibody Response in a Phase 1b 2a Study
Read more →ACIUAC Immune Initiates Clinical Study of First in Class Diagnostic For Parkinson s Disease
AC Immune Initiates Clinical Study of First in Class Diagnostic For Parkinson s Disease
Read more →ACIUAC Immune Reports Progress For Therapeutic Programs Targeting The NLRP3 Inflammasome Pathway
AC Immune Reports Progress For Therapeutic Programs Targeting The NLRP3 Inflammasome Pathway
Read more →ACIUAC Immune Receives Competitive Target ALS Foundation Grant to Accelerate The Development of Proprietary Phosphorylated TDP 43 Immuno Assay
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate The Development of Proprietary Phosphorylated TDP 43 Immuno Assay
Read more →ACIUImmunotherapy Pioneer Prof Carl H June Joins AC Immune s Board of Directors
Immunotherapy Pioneer Prof Carl H June Joins AC Immune s Board of Directors
Read more →ACIUImmunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune's scientific lead
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune's scientific leadership in neurodegeneration Lausanne, Switzerland, November 20, 2020
Read more →ACIUNeurologist And Psychiatrist Prof Johannes Rolf Streffer Md Joins AC Immune SA As Chief Medical Officer
Neurologist And Psychiatrist Prof Johannes Rolf Streffer Md Joins AC Immune SA As Chief Medical Officer
Read more →ACIUNeurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaf
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaffirms AC Immune's scientific leadership in neurodegeneration Lausann
Read more →ACIUAC Immune Reports Q3 2020 Financial Results And Provides Business Update
AC Immune Reports Q3 2020 Financial Results And Provides Business Update
Read more →ACIUAC Immune to Provide Strategy And Pipeline Update During Jefferies Virtual London Healthcare Conference
AC Immune to Provide Strategy And Pipeline Update During Jefferies Virtual London Healthcare Conference
Read more →ACIUAC Immune And Wuxi Biologics Strengthen Strategic Partnership to Accelerate AC Immune s Anti TDP 43 Antibodies Into Clinical Development
AC Immune And Wuxi Biologics Strengthen Strategic Partnership to Accelerate AC Immune s Anti TDP 43 Antibodies Into Clinical Development
Read more →ACIULausanne, 19 October 2020 Invitation to the Extraordinary Shareholders' Meeting Date: Friday, 20 November 2020 | 2:00 PM Central European Time Place: EPFL Innovation Park, Building B | 1015 Lausanne | Switzerland I. Fore
Lausanne, 19 October 2020 the Extraordinary Shareholders' Meeting Date: Friday, 20 November 2020 | 2:00 PM Central European Time Place: EPFL Innovation Park, Building B | 1015 Lausanne | Switzerland I. Foreword 2 II. Agenda 4 1 Election of Carl June as member of the Board of D
Read more →ACIUCompetitive Eu Grant Supports Collaboration to Accelerate Development of AC Immune s First in Class TDP 43 Diagnostic Agent
Competitive Eu Grant Supports Collaboration to Accelerate Development of AC Immune s First in Class TDP 43 Diagnostic Agent
Read more →ACIUAC Immune Reports Top Line Results From Tauriel Phase 2 Trial Evaluating Semorinemab in Early Alzheimer s Disease
AC Immune Reports Top Line Results From Tauriel Phase 2 Trial Evaluating Semorinemab in Early Alzheimer s Disease
Read more →ACIUAC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer's Disease Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer's Disease Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety en
Read more →ACIUAC Immune to Showcase Anti Tau Portfolio at H C Wainwright 22nd Annual Global Investment Conference
AC Immune to Showcase Anti Tau Portfolio at H C Wainwright 22nd Annual Global Investment Conference
Read more →ACIUAC Immune Reports Q2 2020 Financial Results And Provides Business Update
AC Immune Reports Q2 2020 Financial Results And Provides Business Update
Read more →ACIUBalance Sheets (in CHF thousands) Notes As of
Notes As of June 30, 2020 As of December 31, 2019 ASSETS Non-current assets Property, plant and equipment 5 3,770 3,917 Right-of-use assets 6 2,040 2,255 Long-term financial assets 8 304 304 Total non-current assets 6,114 6,476 Current ass
Read more →ACIUAC Immune Initiates IND Enabling Studies For First in Class Antibody Targeting TDP 43 to Treat Neurodegeneration
AC Immune Initiates IND Enabling Studies For First in Class Antibody Targeting TDP 43 to Treat Neurodegeneration
Read more →ACIUAC Immune Wins Prestigious Award to Develop a Game Changing Parkinson s Diagnostic Tool
AC Immune Wins Prestigious Award to Develop a Game Changing Parkinson s Diagnostic Tool
Read more →ACIUAC Immune Demonstrates Enhanced Performance of First in Class Parkinson s Diagnostic Agent
AC Immune Demonstrates Enhanced Performance of First in Class Parkinson s Diagnostic Agent
Read more →ACIUAC Immune to Present Advances in Two of The Company s World Leading Programs at The Upcoming Alzheimer s Association International Conference
AC Immune to Present Advances in Two of The Company s World Leading Programs at The Upcoming Alzheimer s Association International Conference
Read more →ACIUAC Immune Advances phospho-Tau Alzheimer's Vaccine in Phase 1b/2a Study Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35
AC Immune Advances phospho-Tau Alzheimer's Vaccine in Phase 1b/2a Study Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated with the proprietary Supra
Read more →ACIUAC Immune Advances Phospho Tau Alzheimer s Vaccine in Phase 1b 2a Study
AC Immune Advances Phospho Tau Alzheimer s Vaccine in Phase 1b 2a Study
Read more →ACIUTau PET Tracer Pi 2620 Could Set New Standards For an Improved Diagnosis of Progressive Supranuclear Palsy
Tau PET Tracer Pi 2620 Could Set New Standards For an Improved Diagnosis of Progressive Supranuclear Palsy
Read more →ACIUPioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting |
Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting | June 26, 2020 www.acimmune.com Version June 25 11.00am CET Disclaimer This presentation contains statements that constitute "forward - looking statements" within the meaning of Section 27
Read more →ACIUAC Immune Announces Results of Annual General Meeting
AC Immune Announces Results of Annual General Meeting
Read more →ACIUAC Immune CEO to Showcase Novel Target Programs at Ubs Global Healthcare Conference
AC Immune CEO to Showcase Novel Target Programs at Ubs Global Healthcare Conference
Read more →ACIUAC Immune Reports Q1 2020 Financial Results And Provides Business Update
AC Immune Reports Q1 2020 Financial Results And Provides Business Update
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three Months Ended
Condensed Financial Statements (Unaudited) Statements (Unaudited) (IFRS) as of and for the Three Months Ended March 31, 2020 Notes As of March 31, 2020 As of December 31, 2019 ASSETS Non-current assets Property, plant and equipment 5 3,761 3,917 Right-of-
Read more →ACIULausanne 19 May 2020 Invitation to the Ordinary Shareholders' Meeting Date: Friday, 26 June 2020 | 11:00 am Swiss time Place: R. Reagan Room | EPFL Innovation Park, Building B | Ecublens | Switzerland I. Letter to the Sh
Lausanne 19 May 2020 the Ordinary Shareholders' Meeting Date: Friday, 26 June 2020 | 11:00 am Swiss time Place: R. Reagan Room | EPFL Innovation Park, Building B | Ecublens | Switzerland Contact information: AC Immune SA, Investor Services, EPFL Innovation Park, Building B, 10
Read more →ACIUAC Immune Presents The Latest Preclinical Data on Novel Drug Targets For Neurodegenerative Diseases
AC Immune Presents The Latest Preclinical Data on Novel Drug Targets For Neurodegenerative Diseases
Read more →ACIUAC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases Seven presentations by AC Immune and its partners at AAT-AD/PD TM New data on early-stage TDP-43 and alpha
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases Seven presentations by AC Immune and its partners at AAT-AD/PDTM data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates anti-alpha-synuclein ther
Read more →ACIUAC Immune Reports Full Year 2019 Financial Results And Provides 2020 R D Outlook
AC Immune Reports Full Year 2019 Financial Results And Provides 2020 R D Outlook
Read more →ACIUAC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, exc
AC Immune Reports Full-Year 2019 Financial Provides 2020 R&D Outlook Lausanne, Switzerland, March 30, 2020 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced finan
Read more →ACIUAC Immune Receives Second Milestone And New Milestone to Increase The Potential Deal Value of Lilly Morphomer Tau Partnership
AC Immune Receives Second Milestone And New Milestone to Increase The Potential Deal Value of Lilly Morphomer Tau Partnership
Read more →ACIUAC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership CHF 10 million milestone recognizes development progress Updated financial terms
AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership Lausanne, Switzerland, March 23, 2020 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced that it
Read more →ACIUInternationally Renowned Neurologist Dr Juan Fortea Joins AC Immune s Clinical Advisory Board
Internationally Renowned Neurologist Dr Juan Fortea Joins AC Immune s Clinical Advisory Board
Read more →ACIUAC Immune to Present New Data Demonstrating The Depth of Its Neurodegenerative Programs at The Upcoming Advances in Alzheimer s And Parkinson s Therapies Focus Meeting
AC Immune to Present New Data Demonstrating The Depth of Its Neurodegenerative Programs at The Upcoming Advances in Alzheimer s And Parkinson s Therapies Focus Meeting
Read more →ACIUAC Immune to Present at Jefferies 2019 London Healthcare Conference
AC Immune to Present at Jefferies 2019 London Healthcare Conference
Read more →ACIUAC Immune Q3 2019 Financial Results And Business Update
AC Immune Q3 2019 Financial Results And Business Update
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Nine Months Ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Nine Months Ended September 30, 2019 EPFL Innovation Park As of September 30, As of December 31, Note 2019 2018 (in CHF thousa
Read more →ACIUwww.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. Novel Therapeutics and Diagnostics for Neurodegenerative Diseases Andrea Pfeifer, Ph.D., CEO AC Immune Version November 4 2019 AC Immune.
www.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. Novel Therapeutics and Diagnostics for Neurodegenerative Diseases Andrea Pfeifer, Ph.D., CEO AC Immune Version November 4 2019 AC Immune. Not to be used or reproduced without permission. 2 NASDAQ:
Read more →ACIUAC Immune Hosts Key Opinion Leader Event Untangling Tau Pathology to Treat Alzheimer s And Neurodegenerative Diseases
AC Immune Hosts Key Opinion Leader Event Untangling Tau Pathology to Treat Alzheimer s And Neurodegenerative Diseases
Read more →ACIUAC Immune to Host Key Opinion Leader Event Untangling Tau Pathology to Treat Alzheimer s And Neurodegenerative Diseases
AC Immune to Host Key Opinion Leader Event Untangling Tau Pathology to Treat Alzheimer s And Neurodegenerative Diseases
Read more →ACIUAC Immune Receives First Milestone Payment From Lilly in Small Molecule Tau Morphomer Program
AC Immune Receives First Milestone Payment From Lilly in Small Molecule Tau Morphomer Program
Read more →ACIUAC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer de
AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program pay CHF30 million development milestone progress in ACI-3024 Small Molecule Tau Morphomer development Switzerland, September 20, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, cl
Read more →ACIUAC Immune Receives Milestone Payment in Connection With Initiation of a Phase 2 Trial of Tau PET Tracer Pi 2620
AC Immune Receives Milestone Payment in Connection With Initiation of a Phase 2 Trial of Tau PET Tracer Pi 2620
Read more →ACIUAC Immune Awarded Michael J Fox Foundation Grant to Accelerate Development of Parkinson s Disease Diagnostic Imaging Agent
AC Immune Awarded Michael J Fox Foundation Grant to Accelerate Development of Parkinson s Disease Diagnostic Imaging Agent
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Six Months Ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Six Months Ended June 30, 2019 EPFL Innovation Park As of June 30, As of December 31, Notes 2019 2018 (in CHF thousands) ASSET
Read more →ACIUAC Immune Reports Q2 2019 Financial Results Business And Clinical Update
AC Immune Reports Q2 2019 Financial Results Business And Clinical Update
Read more →ACIUAC Immune Announces Research Collaboration With University of Pennsylvania Focusing on Pathogenic Protein TDP 43 in Neurodegenerative Diseases
AC Immune Announces Research Collaboration With University of Pennsylvania Focusing on Pathogenic Protein TDP 43 in Neurodegenerative Diseases
Read more →ACIUAC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer's Disease Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology La
AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer's Disease Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology Lausanne, Switzerland, August 1, 2019 - AC Immune SA (NASDAQ: ACIU), a
Read more →ACIUAC Immune Initiates Ph1b 2a Study of Anti Phospho Tau Vaccine in Alzheimer s Disease
AC Immune Initiates Ph1b 2a Study of Anti Phospho Tau Vaccine in Alzheimer s Disease
Read more →ACIUAC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer , an Investigational Treatment for Alzheimer's Disease Tau Morphomer is the focus of a partnership with Eli Lilly and Company Lausa
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer , an Investigational Treatment for Alzheimer's Disease Tau Morphomer is the focus of a partnership with Eli Lilly and Company Lausanne, Switzerland, July 17, 2019 - AC Immune SA (NASDAQ: ACIU), a Swis
Read more →ACIUAC Immune Initiates Phase 1 Study of ACI 3024 Small Molecule Tau Morphomer an Investigational Treatment For Alzheimer s Disease
AC Immune Initiates Phase 1 Study of ACI 3024 Small Molecule Tau Morphomer an Investigational Treatment For Alzheimer s Disease
Read more →ACIUAC Immune Hosts Kol Event And Reports Initial Interim Clinical Data For ACI 24 Vaccine to Treat Alzheimer s Disease Like Symptoms in Subjects With Down Syndrome
AC Immune Hosts Kol Event And Reports Initial Interim Clinical Data For ACI 24 Vaccine to Treat Alzheimer s Disease Like Symptoms in Subjects With Down Syndrome
Read more →ACIUwww.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. Roadmap to successful therapies for neurodegenerative diseases NASDAQ: ACIU | Annual General Meeting | June 2019 Version June 28 2019 AC I
www.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. Roadmap to successful therapies for neurodegenerative diseases NASDAQ: ACIU | Annual General Meeting | June 2019 Version June 28 2019 AC Immune. Not to be used or reproduced without permission. 2 N
Read more →ACIUAC Immune Announces Election of New Chairman of The Board at Annual General Meeting
AC Immune Announces Election of New Chairman of The Board at Annual General Meeting
Read more →ACIUAC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer s in Down Syndrome
AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer s in Down Syndrome
Read more →ACIUwww.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. ACI - 24 a nti - Abeta vaccine for prevention and therapy in Alzheimer's disease and Down syndrome NASDAQ: ACIU | KOL Breakfast NYC | July
www.acimmune.com 2019 AC Immune. Not to be used or reproduced without permission. ACI - 24 a nti - Abeta vaccine for prevention and therapy in Alzheimer's disease and Down syndrome NASDAQ: ACIU | KOL Breakfast NYC | July 2019 Version 07 July 2019 2019 AC Immune. Not to be used o
Read more →ACIUAC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer s Disease
AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer s Disease
Read more →ACIULausanne, 31 May 2019 Invitation to the Ordinary Shareholders' Meeting Date: 28 June 2019, at 11:30 am Swiss time Place: Rosa Parks Learning Center, ACI offices, EPFL Innovation Park, Building G, South, 1st Floor, 1015 L
Lausanne, 31 May 2019 the Ordinary Shareholders' Meeting Date: 28 June 2019, at 11:30 am Swiss time Place: Rosa Parks Learning Center, ACI offices, EPFL Innovation Park, Building G, South, 1st Floor, 1015 Lausanne In 2018, AC Immune continued to shape the future by discoverin
Read more →ACIUAC Immune Reports Q1 2019 Financial Results And Business Update
AC Immune Reports Q1 2019 Financial Results And Business Update
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three months ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three months ended March 31, 2019 EPFL Innovation Park Notes As of March 31, 2019 As of December 31, 2018 (in CHF thousands) ASSETS Non
Read more →ACIUAC Immune to Present at The H C Wainwright Global Life Sciences Conference
AC Immune to Present at The H C Wainwright Global Life Sciences Conference
Read more →ACIUAC Immune Presents New Data on Alpha Synuclein PET Tracer at AD Pdtm Conference
AC Immune Presents New Data on Alpha Synuclein PET Tracer at AD Pdtm Conference
Read more →ACIUNew Clinical Data on AC Immune s Novel Next Generation Tau PET Tracer Presented By Licensing Partner Life Molecular Imaging at AD PD Tm Conference
New Clinical Data on AC Immune s Novel Next Generation Tau PET Tracer Presented By Licensing Partner Life Molecular Imaging at AD PD Tm Conference
Read more →ACIUAC Immune Reports Full-Year 2018 Financial Results and Provides Business Update CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates Morphomer TM platform In
AC Immune Reports Full-Year 2018 Financial Provides Business Update CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM Initiation of second Phase 2 trial of Tau antibody by partner Genentech Multiple other prod
Read more →ACIUAC Immune Reports Full Year 2018 Financial Results And Provides Business Update
AC Immune Reports Full Year 2018 Financial Results And Provides Business Update
Read more →ACIUAC Immune to Report Progress of Early Stage Pipeline at AD PD Tm Congress
AC Immune to Report Progress of Early Stage Pipeline at AD PD Tm Congress
Read more →ACIUAC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer's Disease Study complements ongoing trial in the prodromal to mild population Lausanne, Switzerland
Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer's Disease complements ongoing trial in the prodromal to mild population Switzerland, February 20, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical compa
Read more →ACIUAC Immune Announces Anti Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer s Disease
AC Immune Announces Anti Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer s Disease
Read more →ACIUAC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development Lausanne, Switzerland
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development Switzerland, February 7, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ann
Read more →ACIUAC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
Read more →ACIUAC Immune Reports Discontinuation of Phase Iii Cread 1 And 2 Studies of Crenezumab in Alzheimer s Disease
AC Immune Reports Discontinuation of Phase Iii Cread 1 And 2 Studies of Crenezumab in Alzheimer s Disease
Read more →ACIUAC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer's Disease Decision follows Independent Data Monitoring Committee analysis The Alzheimer's Prevention Initiativ
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer's Disease Lausanne, Switzerland, January 30, 2019 - AC Immune SA (NASDAQ:ACIU) announced today that Roche, the parent company of its collaboration partner, is discontinuing the CRE
Read more →ACIUAC Immune Announces Appointment of Dr Marie Kosco Vilbois As Chief Scientific Officer
AC Immune Announces Appointment of Dr Marie Kosco Vilbois As Chief Scientific Officer
Read more →ACIUAC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer Lausanne, Switzerland
AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that
Read more →ACIUAC Immune And Wuxi Biologics to Establish an Exclusive Strategic Partnership
AC Immune And Wuxi Biologics to Establish an Exclusive Strategic Partnership
Read more →ACIUAC Immune and Lilly Announce License and Collaboration Agreement Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegen
AC Immune and Lilly Announce License and Collaboration Agreement Lausanne, Switzerland, and Indianapolis, IN, USA, December 12, 2018 - AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) today announced that the two companies have signed a license and collaborati
Read more →ACIUAC Immune And Lilly Announce License And Collaboration Agreement
AC Immune And Lilly Announce License And Collaboration Agreement
Read more →ACIUIn Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away Lausanne, Switzerland
Scientific Leader and Friend Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. is with great sadness that we announce the passing of Dr. Andrea
Read more →ACIUIn Memoriam Dr Andreas Muhs Cso Scientific Leader And Friend Has Passed Away
In Memoriam Dr Andreas Muhs Cso Scientific Leader And Friend Has Passed Away
Read more →ACIUAC Immune Awarded Third Follow Up Grant From The Michael J Fox Foundation For First in Human Study of a Positron Emission Tomography PET Tracer For Parkinson s Disease
AC Immune Awarded Third Follow Up Grant From The Michael J Fox Foundation For First in Human Study of a Positron Emission Tomography PET Tracer For Parkinson s Disease
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three and nine months ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three and nine months ended September 30, 2018 EPFL Innovation Park Note As of September 30, 2018 As of December 31, 2017 in CHF thousands AS
Read more →ACIUAC Immune Reports Third Quarter 2018 Financial Results And Corporate Update
AC Immune Reports Third Quarter 2018 Financial Results And Corporate Update
Read more →ACIUAC Immune to Present at The Jefferies 2018 London Healthcare Conference
AC Immune to Present at The Jefferies 2018 London Healthcare Conference
Read more →ACIUAC Immune Shares Insights From Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer s Disease AD And Other Misfolded Proteins in AD And Neurodegenerative Diseases
AC Immune Shares Insights From Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer s Disease AD And Other Misfolded Proteins in AD And Neurodegenerative Diseases
Read more →ACIUAC Immune to Present at 2018 Society For Neurosciences Meeting
AC Immune to Present at 2018 Society For Neurosciences Meeting
Read more →ACIUAC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer s Disease AD And The Involvement of Other Misfolded Proteins in AD And Neurodegenerative Diseases
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer s Disease AD And The Involvement of Other Misfolded Proteins in AD And Neurodegenerative Diseases
Read more →ACIUAC Immune Partner Life Molecular Imaging Presents New Clinical Study Results For Tau PET Tracer 18f Pi 2620
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results For Tau PET Tracer 18f Pi 2620
Read more →ACIUAC Immune SA New Data Supporting Crenezumab As Potential Alzheimer s Therapy
AC Immune SA New Data Supporting Crenezumab As Potential Alzheimer s Therapy
Read more →ACIUwww.acimmune.com 2018 AC Immune. Not to be used or reproduced without permission. Targeting neurodegenerative diseases with novel therapeutics and diagnostics CTAD late breaking session l O ctober, 2018 2018 AC Immune. N
www.acimmune.com 2018 AC Immune. Not to be used or reproduced without permission. Targeting neurodegenerative diseases with novel therapeutics and diagnostics CTAD late breaking session l O ctober, 2018 2018 AC Immune. Not to be used or reproduced without permission. CTAD | Octo
Read more →ACIUAC Immune Selected to Present Progress on Its Tau Morphomer Program in The Late Breaking News Session at Ctad Conference in Barcelona
AC Immune Selected to Present Progress on Its Tau Morphomer Program in The Late Breaking News Session at Ctad Conference in Barcelona
Read more →ACIUAC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence Lausanne, Switzerland
Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announc
Read more →ACIUAC Immune Announces Dr Andreas Muhs Chief Scientific Officer to Take Medical Leave of Absence
AC Immune Announces Dr Andreas Muhs Chief Scientific Officer to Take Medical Leave of Absence
Read more →ACIUAC Immune Announces Important Clinical Milestones For ACI 24 Vaccine in Alzheimer s Disease And Down Syndrome
AC Immune Announces Important Clinical Milestones For ACI 24 Vaccine in Alzheimer s Disease And Down Syndrome
Read more →ACIUAC Immune Reports Second Quarter 2018 Financial Results And Corporate Update
AC Immune Reports Second Quarter 2018 Financial Results And Corporate Update
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three and six months ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three and six months ended June 30, 2018 EPFL Innovation Park Notes As of June 30, 2018 As of December 31, 2017 in CHF thousands ASSETS
Read more →ACIUAC Immune Announces Successful Closing of Second Subscription Rights Offering
AC Immune Announces Successful Closing of Second Subscription Rights Offering
Read more →ACIUNew Phase 2 Data Analysis For Crenezumab Presented at Global Alzheimer s Conference Provides Strong Evidence For Engagement of The Principle Abeta Target
New Phase 2 Data Analysis For Crenezumab Presented at Global Alzheimer s Conference Provides Strong Evidence For Engagement of The Principle Abeta Target
Read more →ACIUAC Immune Announces Closing of First Subscription Rights Offering And Primary Offering As Well As Full Exercise of Option to Purchase Additional Shares
AC Immune Announces Closing of First Subscription Rights Offering And Primary Offering As Well As Full Exercise of Option to Purchase Additional Shares
Read more →ACIUAC Immune Announces Price of Usd 11 75 For Offerings And Issuance of Up to 10 Million Common Shares
AC Immune Announces Price of Usd 11 75 For Offerings And Issuance of Up to 10 Million Common Shares
Read more →ACIUAC Immune Announces Offerings And Issuance of Up to 10 Million Common Shares
AC Immune Announces Offerings And Issuance of Up to 10 Million Common Shares
Read more →ACIUCrenezumab s Second Phase 3 Trial Cread 2 Fully Recruited Updates on AC Immune s Pipeline And Technology Platforms to Be Presented at Aaic in Chicago
Crenezumab s Second Phase 3 Trial Cread 2 Fully Recruited Updates on AC Immune s Pipeline And Technology Platforms to Be Presented at Aaic in Chicago
Read more →ACIUCrenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference in Chicago Laus
Second Phase 3 Trial (CREAD 2) Fully Recruited on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmace
Read more →ACIUBECOMING A GLOBAL LEADER IN PRECISION MEDICINE OF NEURODEGENERATIVE DISEASES 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | AGM |
BECOMING A GLOBAL LEADER IN PRECISION MEDICINE OF NEURODEGENERATIVE DISEASES 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | AGM | July 6, 2018 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM |
Read more →ACIULausanne, 6 June 2018 Invitation to the Ordinary Shareholders' Meeting Date: 6 July 2018, at 10.30 am Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne Dear Shareholder,
Lausanne, 6 June 2018 to the Ordinary Shareholders' Meeting Date: 6 July 2018, at 10.30 am Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne We are pleased to report that AC Immune has continued to make significant progress in
Read more →ACIUAC Immune Reports First Quarter 2018 Financial Results And Corporate Update
AC Immune Reports First Quarter 2018 Financial Results And Corporate Update
Read more →ACIUAC Immune Announces Results of Extraordinary Shareholders Meeting
AC Immune Announces Results of Extraordinary Shareholders Meeting
Read more →ACIUNOVEL THERAPEUTICS AND DIAGNOSTICS FOR ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | EGM |
NOVEL THERAPEUTICS AND DIAGNOSTICS FOR ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | EGM | April 27, 2018 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ:
Read more →ACIUAC Immune Announces The Selection of Tau Small Molecules For Clinical Development in Alzheimer s Disease
AC Immune Announces The Selection of Tau Small Molecules For Clinical Development in Alzheimer s Disease
Read more →ACIULausanne, 22 March 2018 Invitation to the Extraordinary Shareholders' Meeting Date: 27 April 2018, at 15.00 pm Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne Dear Shar
Lausanne, 22 March 2018 to the Extraordinary Shareholders' Meeting Date: 27 April 2018, at 15.00 pm Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne have the pleasure of informing you that the following industry expert has rec
Read more →ACIUAC Immune reports full-year 2017 financial results - successful first year as a public company Lausanne, Switzerland
reports full-year 2017 financial results - successful first year as a public company Switzerland, March 20, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced f
Read more →ACIUAC Immune Reports Full Year 2017 Financial Results Successful First Year As a Public Company
AC Immune Reports Full Year 2017 Financial Results Successful First Year As a Public Company
Read more →ACIUAC Immune Prepares For a First in Human Study of a Promising Positron Emission Tomography PET Tracer For Parkinson s Disease
AC Immune Prepares For a First in Human Study of a Promising Positron Emission Tomography PET Tracer For Parkinson s Disease
Read more →ACIUAC Immune to Participate in Two Investor Conferences And Provide Scientific Updates at Aat AD PD Conference
AC Immune to Participate in Two Investor Conferences And Provide Scientific Updates at Aat AD PD Conference
Read more →ACIUAC Immune Shares Insights From Key Opinion Leader Meeting on Tau As a Therapeutic And Diagnostic Target in Alzheimer s And Other Neurodegenerative Diseases
AC Immune Shares Insights From Key Opinion Leader Meeting on Tau As a Therapeutic And Diagnostic Target in Alzheimer s And Other Neurodegenerative Diseases
Read more →ACIUAC Immune to Host Key Opinion Leader Meeting on Tau As a Therapeutic And Diagnostic Target in Alzheimer s And Other Neurodegenerative Diseases
AC Immune to Host Key Opinion Leader Meeting on Tau As a Therapeutic And Diagnostic Target in Alzheimer s And Other Neurodegenerative Diseases
Read more →ACIUAC Immune SA Reports Third Quarter 2017 Financial Results And Corporate Update
AC Immune SA Reports Third Quarter 2017 Financial Results And Corporate Update
Read more →ACIUAC Immune to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease AC Immune to receive third milestone payment of CHF 14 million under collaboration agreement wi
AC Immune to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease Lausanne, Switzerland, November 2, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurod
Read more →ACIUAC Immune SA to Receive Milestone Payment For Anti Tau Antibody Moving Into Phase 2 Trial For Alzheimer s Disease
AC Immune SA to Receive Milestone Payment For Anti Tau Antibody Moving Into Phase 2 Trial For Alzheimer s Disease
Read more →ACIUAC Immune to Present at Two Investor Conferences And Provide Scientific Updates at Ctad Conference
AC Immune to Present at Two Investor Conferences And Provide Scientific Updates at Ctad Conference
Read more →ACIUAC Immune Awarded Continuation of 2015 Grant From The Michael J Fox Foundation For Parkinson s Research
AC Immune Awarded Continuation of 2015 Grant From The Michael J Fox Foundation For Parkinson s Research
Read more →ACIUAC Immune Completes Recruitment For Low Dose Cohort in World s First Clinical Trial For Anti Abeta Vaccine Targeting Alzheimer s Disease Like Characteristics in Individuals With Do
AC Immune Completes Recruitment For Low Dose Cohort in World s First Clinical Trial For Anti Abeta Vaccine Targeting Alzheimer s Disease Like Characteristics in Individuals With Do
Read more →ACIUAC Immune Discovers Next Generation Antibodies Focused on Neurodegenerative Diseases
AC Immune Discovers Next Generation Antibodies Focused on Neurodegenerative Diseases
Read more →ACIUAC Immune Reports Second Quarter 2017 Financial Results
AC Immune Reports Second Quarter 2017 Financial Results
Read more →ACIUAC Immune Provides Seven Updates on Its Pipeline And Technology at The Alzheimer s Association International Conference
AC Immune Provides Seven Updates on Its Pipeline And Technology at The Alzheimer s Association International Conference
Read more →ACIUNOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER'S www.acimmune.com Annual General Meeting | Lausanne |
NOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER'S www.acimmune.com Annual General Meeting | Lausanne | June 28, 2017 2017 AC Immune. Not to be used or reproduced without permission. 2017 AC Immune. Not to be used or reproduced without permi
Read more →ACIULausanne, 30 May 2017 Invitation to the Ordinary Shareholders' Meeting Date: 28 June 2017, at 11.00 am Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne Dear Shareholder,
Lausanne, 30 May 2017 the Ordinary Shareholders' Meeting Date: 28 June 2017, at 11.00 am Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne 2016 was an exciting landmark year for AC Immune. Through our successful IPO on the US
Read more →ACIUAC Immune And Essex Bio Technology Announce Research Collaboration For Neurodegenerative Diseases And Neuroinflammation
AC Immune And Essex Bio Technology Announce Research Collaboration For Neurodegenerative Diseases And Neuroinflammation
Read more →ACIUInterim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three month period ended
Interim Condensed Financial Statements (Unaudited) Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three month period ended March 31, 2017 EPFL Innovation Park Interim Condensed Financial Statements (Unaudited) Notes As of March 31, 2017 As o
Read more →ACIUAC Immune SA Reports First Quarter 2017 Financial Results
AC Immune SA Reports First Quarter 2017 Financial Results
Read more →ACIUPiramal Imaging And AC Immune Present First Clinical Data For Tau PET Imaging Tracer at International Alzheimer s Conference
Piramal Imaging And AC Immune Present First Clinical Data For Tau PET Imaging Tracer at International Alzheimer s Conference
Read more →ACIUAC Immune Provides Twelve Updates on Its Pipeline at The International Conference on Alzheimer s And Parkinson s Diseases
AC Immune Provides Twelve Updates on Its Pipeline at The International Conference on Alzheimer s And Parkinson s Diseases
Read more →ACIUAC IMMUNE reports Full year 2016 financial results and R&D update Strong cash position of CHF 152.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Succes
IMMUNE reports Full year 2016 financial results Switzerland, March 17, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced financial results for the full year ended December 31, 2016.
Read more →ACIUAC Immune Reports Full Year 2016 Financial Results And R D Update
AC Immune Reports Full Year 2016 Financial Results And R D Update
Read more →ACIUAC Immune Partner Genentech to Start Second Phase 3 Clinical Trial For Alzheimer s Therapy Crenezumab
AC Immune Partner Genentech to Start Second Phase 3 Clinical Trial For Alzheimer s Therapy Crenezumab
Read more →ACIUCrenezumab Phase I Study 2016 AC Immune. Not to be used or reproduced without permission. 2016 AC Immune. Not to be used or reproduced without permission. 2 Crenezumab Background Crenezumab (RO5490245) is a humanized ant
Crenezumab Phase I Study 2016 AC Immune. Not to be used or reproduced without permission. 2016 AC Immune. Not to be used or reproduced without permission. 2 Crenezumab Background Crenezumab (RO5490245) is a humanized anti - amyloid monoclonal IgG4 antibody Binds multiple forms o
Read more →ACIUAC Immune Partner Genentech Presents Important Data on Alzheimer s Therapy Crenezumab
AC Immune Partner Genentech Presents Important Data on Alzheimer s Therapy Crenezumab
Read more →ACIUAC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER Lausanne, Switzerland
AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER Lausanne, Switzerland, November 23, 2016 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that it
Read more →ACIUAC Immune SA Announces Results of Annual General Meeting
AC Immune SA Announces Results of Annual General Meeting
Read more →ACIUwww.acimmune.com 2016 AC Immune - Not to be used or reproduced without permission. NOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER'S Annual General Meeting l
www.acimmune.com 2016 AC Immune - Not to be used or reproduced without permission. NOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER'S Annual General Meeting l November 15, 2016 2016 AC Immune. Not to be used or reproduced without permission.
Read more →ACIUUnaudited interim condensed financial statements Unaudited interim condensed financial statements (IFRS) as at and for the period ended
interim condensed financial statements interim condensed financial statements (IFRS) as at and for the period ended September 30, 2016 EPFL Innovation Park Unaudited interim condensed financial statements in CHF thousands As at September 30, As at December 31, Notes 2
Read more →ACIUAC Immune Reports Third Quarter 2016 Results
AC Immune Reports Third Quarter 2016 Results
Read more →ACIUAC Immune SA Reports Third Quarter 2016 Results
AC Immune SA Reports Third Quarter 2016 Results
Read more →ACIULausanne, 7 October 2016 Invitation to the Ordinary Shareholders' Meeting Date: 15 November 2016, at 10.30 Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne Dear Sharehol
Lausanne, 7 October 2016 the Ordinary Shareholders' Meeting Date: 15 November 2016, at 10.30 Swiss time Place: EPFL Innovation Park Building D, ground floor, Uranus Meeting room, 1015 Lausanne We would like to take this opportunity to warmly welcome the investors who recently
Read more →ACIUSwitzerland s AC Immune Opens For Trading on NASDAQ
Switzerland s AC Immune Opens For Trading on NASDAQ
Read more →ACIUAC Immune SA Announces Pricing of Upsized Initial Public Offering
AC Immune SA Announces Pricing of Upsized Initial Public Offering
Read more →ACIUAC Immune SA Commences Proposed Initial Public Offering of Common Shares
AC Immune SA Commences Proposed Initial Public Offering of Common Shares
Read more →Competitive Position
How ACIU ranks across every disease it competes inCompetitive Position is a premium feature
See how ACIU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial